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Abstract A major source of drug attrition in pharmaco-
logical development is drug toxicity, which eventually
manifests itself in detrimental physiological effects. These
effects can be assessed in large sample cohorts, but gen-
erating rich sets of output variables that are necessary to
predict toxicity from lower drug dosages is problematic.
Currently the throughput of methods that enable multi-
parametric cellular readouts over many drugs and large
ranges of concentrations is limited. Since metabolism is at
the core of drug toxicity, we develop here a high-
throughput intracellular metabolomics platform for relative
measurement of 50–100 targeted metabolites by flow
injection-tandem mass spectrometry. Specifically we
focused on central metabolism of the yeast Saccharomyces
cerevisiae because potential cytotoxic effects of drugs can
be expected to affect this ubiquitous core network. By
machine learning based on intracellular metabolite
responses to 41 drugs that were administered at seven
concentrations over three orders of magnitude, we dem-
onstrate prediction of cytotoxicity in yeast from
intracellular metabolome patterns obtained at much lower
drug concentrations that exert no physiological toxicity.
Furthermore, the 13C-determined intracellular response of
metabolic fluxes to drug treatment demonstrates the func-
tional performance of the network to be rather robust, until
growth was compromised. Thus we provide evidence that
phenotypic robustness to drug challenges is achieved by a
flexible make-up of the metabolome.
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1 Introduction
Predicting cellular behavior at the molecular level is an
enormous challenge. One of the prerequisites for this
endeavor is knowledge of the interactions between and
responses to perturbations of the various molecules that
make up cells. While our ability to interrogate gene–gene,
protein–protein and protein–DNA interactions has greatly
improved, methods to unravel metabolite–protein interac-
tions or to quantify response to alterations in metabolite
levels—both natural and artificial—are much less devel-
oped. The so far most successful approach is based on
external supplementation of small molecules in so-called
chemical genomics, most powerfully applied in combination
with mutant libraries for systematic testing of condition-
specific genotype—phenotype associations (Hillenmeyer
et al. 2008; Kapitzky et al. 2010; Lehar et al. 2008; Perlstein
et al. 2007). While large numbers of combinatorial pertur-
bations can be tested in parallel, typically only growth is
quantified to identify functional interactions between added
compound and modified gene. Slightly larger numbers of
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output variables can be screened through cell-based assays as
exemplified by successful probing of four oxidative phos-
phorylation parameters (Wagner et al. 2008). Image-based
assays can further expand the scope by extracting either
individual optical features in the acquired images or more
complex phenotypic traits from feature patterns (Perlman
et al. 2004; Wagner and Clemons 2009; Young et al. 2008).
In general, an inverse relationship exists between the extent
of multiplexing and throughput of an assay (Feng et al.
2009). For primary screening of drug responses that requires
high-throughput, the current practice is therefore targeted
monitoring of up to a handful of cellular parameters or
image-based detection of high level, multifactorial pheno-
typic traits.
In particular for drug development, however, richer data
sets with tens to thousands of measured variables are nec-
essary to address the key problems of target identification,
mode of action, metabolic fate, biomarkers or toxicity. For
many of these questions, metabolism is at the core of the
matter because drug targets are often enzymes, enzymes
convert drugs, drugs have metabolic consequences that
might be exploitable as biomarkers, or because the drugs
themselves or their metabolic products exhibit toxic effects.
It is thus paramount to develop multi-variable assays that
monitor the functional output of metabolism, which should
be either at the level of fluxes or concentrations of metab-
olites (Coen et al. 2008; Ellis et al. 2007; Kaddurah-Daouk
et al. 2008; Sauer 2004; Turner and Hellerstein 2005). A
sufficiently high level of throughput is pivotal to exploit the
potential of small-molecule phenotypic profiling in drug
discovery and development (Wagner and Clemons 2009). In
contrast to the powerful multi-variable output of transcrip-
tomic or proteomic analyses that is simply neither feasible
nor affordable on thousands of samples (Feng et al. 2009),
mass spectrometry (MS)-based metabolomics (Zamboni and
Sauer 2009) or fluxomics (Zamboni and Sauer 2004) are, in
principle, capable of the required throughput. While flux-
based methods assess the integrated functional network
output of all molecular regulation and catalytic interactions
(Hellerstein 2003; Sauer 2006), metabolite-based methods
can sensitively reveal local responses of metabolism to
perturbations (Boer et al. 2010; Fendt et al. 2010a).
In pharmacological development, the two major sources
of drug attrition are efficacy and toxicity (Hopkins 2008),
where toxicity testing in the twenty-first century is con-
sidered to rely on high-throughput tests in cell lines and
dose–response modeling (Andersen and Krewski 2009;
Committee on Toxicity Testing and Assessment of Envi-
ronmental Agents 2007). One of the gaps between this
grand vision and the current practice is that almost all
functional screens are done at a single, physiologically
effective drug concentration and not over large dose ranges
(Perlman et al. 2004). Here we attempt to fill this gap by
developing a high throughput metabolomics method that
enables prediction of cytotoxic drug effects by a machine-
learning approach from a small number of assays at low
drug dosages. As a proof of concept, we focused on central
metabolism of the yeast Saccharomyces cerevisiae because
potential cytotoxic effects of drugs can be expected to
directly or indirectly affect this ubiquitous core network.
2 Materials and methods
2.1 Strains, chemicals, and media
Reagents (Supplementary Table 1) were purchased from
Sigma Aldrich and stored at -20C until use. Each com-
pound was dissolved in dimethyl sulfoxide (DMSO), with
the exception of the water-dissolved drugs ara-CMP, caf-
feine, phenformin, doxorubicin, hydroxyurea, 2-deoxyglu-
cose, oxythiamin, malonate and sodium iodoacetate. All
experiments were performed with the S. cerevisiae strain
FY4 MATa. Cultures were initially propagated in YPD plates
and then grown in defined minimal medium (Verduyn et al.
1992) with 1% (w/v) glucose as the sole carbon source. The
medium was buffered with 10 mM KH-phthalate (pH 5.0).
2.2 Drug treatment
To determine appropriate drug concentrations, a dilution
series of each compound was made with either water or
DMSO for five dilution steps, where the starting concen-
trations were chosen based on literature data. A 100 ll (for
water-solved drugs) or 5 ll for (for DMSO-solved drugs)
aliquot of each dose or control (e.g. water or DMSO) was
distributed to a 96 deep-well plate (Ku¨hner AG, Switzer-
land) in triplicate in 1.2 ml of minimal medium. From an
overnight preculture, cells were added to each of the 96
wells to a final OD600 of 0.05. Plates were then incubated at
30C on a rotary shaker at 300 rpm with 5 cm amplitude.
The exponential growth phase of each culture was moni-
tored by measuring the optical density at 600 nm (OD600)
in a spectrophotometer (Molecular Devices, USA), and the
maximal specific growth rate was determined by log-linear
regression of OD600 versus time, with specific growth rate
(lmax) as the regression coefficient. Based on these data,
we chose seven concentrations for each drug that cover
four orders of magnitude.
2.3 Cultivation and metabolome sampling for shake
flasks
Yeast cultivations were performed in duplicate 500 ml-
baffled shake flask (250 rpm), at 30C in minimal medium.
Each flask contained 100 ml of minimal medium. From
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biological triplicate experiments, 1 ml aliquots of the mid-
exponential growth phase at an OD600 of unity were rapidly
withdrawn by pipetting, and quenched in 4 ml -40C pre-
cooled 60% (v/v) methanol with 10 mM ammonium acetate
at pH 7.5. Biomass was separated from the quenching solu-
tion by rapid centrifugation at 10,000 rpm for 1 min at
-20C, and metabolites were extracted immediately by
adding 1 ml 80C 75% (v/v) ethanol containing 10 mM
ammonium acetate at pH 7.5. The mixture was incubated for
3 min at 80C and then immediately chilled in an ice bath
for 3 min. Cell debris was separated by centrifugation at
10,000 rpm for 10 min at 4C. The supernatant was dried at
30C and 0.12 mbar using a Christ RVC2-33 concentrator
vacuum system connected to Christ Alpha 2-4 LD plus freeze
dryer (both from Ku¨hner AG, Switzerland). After evapora-
tion of the solvent, samples were stored at -80C.
2.4 Cultivation and metabolome sampling for filter
plates
To enable large scale metabolome analysis, batch growth
experiments were carried out in 96-well plates with PES
0.45 lm filter on the bottom (Interchim, France). Wells
were filled with 1.2 ml minimal medium, using four rep-
licate wells per condition and 12 for the control. Inocula-
tion was done with from overnight precultures to a final
starting OD600 of 0.05. Filter plates were incubated at 30C
using an orbital shaker with 5 cm amplitude at 300 rpm. To
ensure appropriate mixing, one 4 mm diameter glass bead
(Sigma-Aldrich, Switzerland) was added to each deep-well.
Aliquots were withdrawn during the mid-exponential phase
defined as an OD600 between 0.5 and 1.5). Supernatant was
removed by vacuum-filtration through the well bottom
within 30 s. The filter plate with retained cell pellets was
then quickly frozen with liquid nitrogen. Thus, quenching
was achieved within 50 s, and the results were consistent
for most of the tested metabolite levels in control shake
flask experiments with 15 s quenching (Supplementary
Table 3). Metabolites were extracted from frozen pellets by
adding 0.5 ml of extraction solvent (75% (v/v) ethanol,
10 mM ammonium acetate at pH 7.4) at -20C to each
well, followed by incubation in a water bath at 80C for
3 min. The liquid extracts were then collected into a
96-well collection plates by vacuum-filtration through the
well bottom The pellets were washed once with 0.5 ml of
extraction solvent and the resulting extracts transferred in
the same collection plate to yield ca. 1 ml total extract.
These were dried and stored as described above.
2.5 High-throughput metabolomics
The flow injection analysis was performed using an Agilent
1100 Series HPLC System coupled to an Applied
Biosystems/MDS SCIEX 4000 QTRAP instrument equip-
ped with the TurboV electrospray interface. The samples
from the evaporated plate were resuspended in 80 ll dis-
tilled water and 5 ll were transferred into a 96-well PCR
plate (ABgene, UK) and then placed at 4C in the auto-
sampler. One microliter sample was injected in 75% (v/v)
methanol, 5 mM ammonium carbonate at pH 9 with a flow
rate of 0.1 ml/min. Spectra were collected in negative
mode and in multiple reaction monitoring. A total of 68
transitions were acquired with 30 ms dwell time, and total
cycle time of 2.3 s. The routine throughput was of about 60
injections per hour, and was primarily set by the time
necessary for cleaning of the injector and flushing of the
ionization chamber to reduce carryover. The electrospray
source was operated at 4.5 kV and 650C. Compound-
specific settings were the same as in reference (Buscher
et al. 2009). Data were recorded and analyzed with Analyst
Software Version 1.4.2. For purposes of validation, extracts
of yeast were prepared from 96-well filter plates as
described. To assess linearity, we prepared a dilution series
with such extracts and applied linear regression to the
integrated peak areas for 68 compounds. To estimate intra-
and inter-day MS reproducibility, two different extracts
from yeast cells grown in the same filter plate were split in
two and stored at -80C. The first fractions were analyzed
four times on Day 1 and the remaining fractions were
analyzed four times on Day 2. To approximate both inter-
and intra- cultivation and sampling reproducibility, three
different extracts from yeast cells grown in the same filter
plate plus three different extracts from yeast grown in three
different filter plates on three different days were all ana-
lyzed by flow injection-MS on the same day. For com-
parison, signals were normalized by dividing the peak area
obtained for each metabolite with the OD600 of the culture.
2.6 Metabolomics data processing
For each sample, integrated metabolite areas were nor-
malized with the corresponding OD at the time point of
sampling and averaged over all replicates (n = 4 for
drugged cells, n = 12 for controls). To ensure quality,
metabolite concentrations for which either less than three
replicas were measured or the relative error was larger than
35%, were removed from the design matrix and indicated
as ‘‘missing’’. The data was sorted by increasing drug
concentration. Missing values were imputed linearly with
the average of their closest neighbors with lower and
higher concentration if both neighbors are measured.
Metabolites which still comprised missing values were
removed from the corresponding drug experiment. All
metabolite areas were first normalized with the average
area measured for the same metabolite in the (un-drugged)
control and second by log2 transformation resulting in fold
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changes. Finally, metabolites were removed, which showed
erratic behavior (i.e. single concentration spikes with a fold
change of more than 0.6.).
For every profile of growth rates given by one drug at
increasing concentration, we determined the maximum
non-toxic concentration, which is the highest drug dose
which does not affect the growth rate. This maximum non-
toxic concentration is defined as the point xi in the growth
rate profile for which xiþ1  avg xiþ1; xi; xi1f gð Þj j[ 0:02.
2.7 Toxicity prediction
To potentially predict the occurrence of drug toxicity from
metabolome measurements from the minimal number of
sub-toxic concentrations, we attempted to train a general
classifier for all drugs from the raw MS data. For each
drug, we considered only drug concentrations lower or
equal to the maximum non-toxic concentration, since pre-
dicting toxicity at a concentration at which toxicity is
detectable at macroscopic scale is trivial. The design
matrix X for the classifier consists of metabolite concen-
tration frames. A frame is defined as triplet of three
consecutive drug concentrations, for each of which 68
non-filtered metabolite fold-changes were available and
concatenated to form a single feature vector of length 204.
These frames are overlapping, hence resulting in five
frames for a drug, for which seven concentrations were
measured and which showed no growth rate effect. For
toxic drugs all doses above the maximum non-toxic con-
centration were neglected, and thus fewer frames could be
extracted. The target variable Y of the model is dependent
on the growth rate profile of the drug. The frames were
labeled based on the future onset of a growth rate effect of
the drug, e.g. a frame consisting of concentrations two,
three and four was labeled as ‘‘toxic’’ if the maximum non-
toxic concentration was five or six. In the case of non-toxic
drugs all five frames were labeled as ‘‘non-toxic’’.
One of the key challenges in this setting is the large
number of missing values due to the rigorous quality control
procedure. To overcome this problem we facilitated a
k-nearest neighbor (kNN) classifier which operates only on
pairwise distances instead of using the whole design matrix
at once (Hastie et al. 2009). The Euclidean distance was
used to determine neighbors in the 204-dimensional feature
space and k was set to 3. To accommodate the fact that only
one-third of all frames are flagged as toxic and the impor-
tance of high sensitivity in toxicity classification, a test
sample was classified as ‘‘toxic’’ if one or more of its three
nearest neighbors was ‘‘toxic’’. Prediction performance is
measured with class balanced error rate. The main difficulty
in learning a kNN classifier is feature selection, which aims
at finding a subset of metabolites that yield the best per-
formance in terms of toxicity prediction. The underlying
hypothesis is that not all metabolite measurements are
indicative for future toxicity and therefore contaminate the
distance measure. In addition, since MS detection suffers
from an intrinsic tradeoff between number of metabolites
and precision, feature selection enables to prioritize MS
detection and thus favorably affects data quality. To this end
we implemented a forward–backward selection procedure,
which optimizes the balanced error rate by adding and
removing features until convergence (Hastie et al. 2009).
The resulting subset is then used to predict the toxicity of
the left out test samples. The learning procedure yields a
toxicity model with a training error of 9%.
We validated the classifier with two cross validation
experiments. The first one was a leave one out cross vali-
dation on drug level. Hence all frames of a drug were left
out of training and subsequently were predicted by the
learned kNN model. This was repeated for each drug
resulting in a prediction error of 24% (Supplementary
Fig. 6). The aim of the second validation experiment was
to ensure that the whole training and selection procedure is
not over fitting., To this end 100 permutation tests were
conducted for leave-one-drug-out cross validation. At each
run the target variable Y was randomly permuted and the
complete training and testing procedure was repeated with
these permuted labels. The resulting average balanced error
rate of 51% demonstrates that the learning procedure is not
over fitting (Supplementary Fig. 6).
2.8 13C metabolic flux analysis
Duplicate labeling experiments were carried out in 96 deep-
well plate (Ku¨hner AG, Switzerland) in 1.2 ml of minimal
medium on 10 g/l glucose as a mixture of 80% (w/w) nat-
urally and 20% (w/w) [U-13C] labeled glucose (13C C 99%,
Cambridge Isotope Laboratories, USA). Each of the 41
compounds was administered at two concentrations as
described in the main text. Cells from overnight cultures
were harvested by centrifugation and washed using sugar
free minimal medium to remove residual, unlabeled carbon
source. Cultures were inoculated to an OD600 of 0.05 and
harvested during mid-exponential growth (OD600 0.5–1.2)
by centrifugation. Residual medium was removed by
washing the pellet three times with water and cells were
stored at -20C. Samples for gas chromatography–MS
analysis were prepared as described previously (Blank et al.
2005) on a 6890N instrument with a 5973 Inert XL MS
system (Agilent Technologies). Flux ratios were determined
from the mass isotopologue distribution of the protein-
bound amino acids with the software FiatFlux (Zamboni
et al. 2005) using the analytical equations developed by
Fischer and Sauer (2003). The mass isotopologue distribu-
tion was corrected for the amount of unlabelled biomass and
stable natural isotopes (Fischer and Sauer 2003).
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3 Results and discussions
3.1 Physiological test of drug cytotoxicity in yeast
To demonstrate characterization and prediction of drug-
induced toxicity at the functional level of metabolism, we
assembled a set of 41 heterogeneous drugs (Supplementary
Table 1). They were chosen to include (i) diverse mecha-
nisms of toxic or therapeutic action in metabolic diseases
or against fungal invasion; (ii) structurally diverse mole-
cules with common targets; (iii) a wide range of metabolic
targets; and (iv) some non-metabolic targets including
signaling networks, transporters, DNA replication and cell
division. Of the 34 drugs with known targets in yeast
metabolism, ten are inhibitors of enzymes in central and
amino acid metabolism. For each compound, we performed
quantitative miniscale yeast growth experiments to assess
its dose-dependent toxicity, defined here as a decrease in
the specific growth rate. Based on this initial physiological
characterization, we chose the concentration causing a 50%
reduction in growth rate as the highest dosage for our
experiments. Starting from this drug-specific maximum
concentration, we used seven sequentially lower drug
concentrations that cover a range of four orders of mag-
nitude (Supplementary Table 2). We thereby achieved
at least four sub-toxic concentrations for all drugs (Fig. 1;
Supplementary Fig. 1 for details). For 21 com-
pounds, notably titration up to the maximum solubility
did not cause any detectable growth rate effect at any
concentrations.
Fig. 1 Yeast growth rate response to increasing drug concentrations.
For each drug, eight drug concentrations were chosen to uniformly
span over four orders of magnitude and such that the highest dosage
(#8) corresponds to the IC50 for yeast. Drugs were grouped by the
onset of growth inhibition. Growth rates of one representative drug
are shown (indicated by an asterisk). Vertical red lines indicate the
highest non-toxic concentration. For absolute drug concentrations
please consult Supplementary Table 2
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3.2 Assessing drug toxicity by 13C metabolic flux
analysis
Assuming that drugs are toxic because they inhibit essen-
tial pathways or perturb the overall energy and redox bal-
ance, we hypothesized that these effects could be reflected
in changes of the intracellular reaction rates, triggered
either passively by enzyme inhibition or actively by the
cell to maintain homeostasis. Hence, we experimentally
determined in vivo pathway activity by 13C-metabolic flux
analysis (Sauer 2006; Zamboni et al. 2009) at two drug
concentrations; i.e. the highest, often toxic concentration
and the third lowest, always non-toxic concentration in the
dilution series (Supplementary Table 2). The experiment
consisted of growing yeast cultures on 13C-labeled glucose
and computing seven independent ratios of converging
intracellular pathways from the 13C-pattern recorded in
proteinogenic amino acids by MS (Fischer and Sauer 2003;
Sauer 2006; Zamboni et al. 2009). These ratios of con-
verging fluxes provide a precise overview on carbon fluxes
around key nodes within central metabolism. At the highest
dosage, only nine drugs elicited minor flux changes that
were probably an indirect consequence of altered physiol-
ogy because the flux changes were rather similar
(Supplementary Fig. 2). More important, virtually no flux
effect could be detected at the sub-toxic drug concentra-
tions. Thus, metabolism is either impressively resilient to
chemical perturbations or the employed flux method is not
sufficiently sensitive to detect shifts that might occur in
peripheral pathways. In either case, we concluded that such
flux analysis is not pertinent for toxicity assessment.
3.3 Development of a high-throughput metabolomics
method
As an alternative to flux analysis, we set out to investigate
the metabolome response to drug treatment. In particular
we wanted to exploit the recently demonstrated local sen-
sitivity of metabolite concentrations to perturbations of
enzyme activity, in particular when fluxes are invariant as
can be expected when growth remains unaffected (Fendt
et al. 2010a). To enable analysis of large sample cohorts in
reasonable time, we established a high-throughput meta-
bolomics platform for relative measurement of 50–100
metabolites in thousands of samples. The resulting work-
flow is depicted in Fig. 2a. Briefly, cultivation was per-
formed in 96-well filter plates that enable comparable
growth rates to shake flasks, and rapid quenching within
a b
Fig. 2 High-throughput
metabolomics workflow.
a Analytical workflow. Yeast
cells were grown in 96-well
plates with filter bottom. For
rapid quenching of metabolic
activity, the medium was
removed by suction and cell
pellets on the filter were rapidly
frozen in liquid nitrogen.
Metabolites were extracted with
buffered hot ethanol, and
measured after flow injection on
a triple quadrupole mass
spectrometer at a rate of 1
sample/min. A total of 55 out of
68 targeted metabolites
exhibited sufficient linearity and
reproducibility for relative
quantification. b Data
processing workflow. An
exemplary subset of six
metabolite profiles is shown for
a given drug. Raw data were
first smoothed (red line) and
noisy curves were filtered out.
The earliest point of deflection
from the control concentration
(vertical green line) is detected
as described in Sect. 2, and used
to classify the profile (compare
Fig. 1)
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50 s of biochemical activity was achieved by vacuum-fil-
tering before solvent treatment. Intracellular metabolites
were subsequently extracted using a standard procedure
adapted to fit the here employed filter-based cell harvest,
with a global recovery vs. standard protocol of typically
above 75% (Supplementary Table 3). In total, about
10 min are required to process a plate with 96 cultures.
Cell extracts were analyzed by flow injection-tandem
MS at a routine throughput of at least 1,200 samples/day.
Mass spectrometer acquisition was initially devised to
target 68 metabolites, corresponding to most intermediates
of glycolysis, pentose-phosphate pathway, and the TCA
cycle, as well as representatives of amino acids, nucleo-
tides, polysaccharides, vitamins, and lipid precursors
(Supplementary Table 4). From the original list of 68
intermediates, 13 failed quality control because of insuffi-
cient signal-to-noise, linearity, or reproducibility. For all of
the 55 remaining metabolites, the mass spectrometer
response was linear to the amount with R2 [ 0.90, and
R2 [ 0.95 for more than 40 metabolites (Supplementary
Table 5).
Before attempting a large screen, we tested all relevant
reproducibility parameters. Intra-day and inter-day repeat-
ability were found to have average relative standard devi-
ations of 14% and 17%, respectively (Supplementary
Fig. 3). Similarly, sample-to-sample variability exhibited
an average relative standard deviation of 19% within the
same plate and 24% between plates, indicating that bio-
logical variability is larger than the technical precision.
Further, noise and robustness were tested with yeast cells
grown in the presence of compounds generally regarded to
be inactive on yeast metabolism. As expected, most tested
compounds did not affect the measurable metabolome. The
only exception was xylose that cannot be utilized by yeast
(Sonderegger and Sauer 2003), but surprisingly produced a
specific metabolome pattern in its catabolic route (Sup-
plementary Figs. 4, 5).
3.4 Assessing drug cytotoxicity by high-throughput
metabolomics
To diagnose the effect of drugs on metabolism, we recor-
ded metabolome profiles with our high-throughput plat-
form from more than 1,500 samples, comprising 41 drugs
at seven concentrations from four biological replicates plus
controls. For each sample, 55 metabolites were measured,
yielding more than 100,000 data points in total. To qualify
drug effects, we generated dose–response curves that
describe the relationship between metabolite changes and
drug concentrations (Fig. 2b). Noisy signals and erratic
profiles were neglected. For a one glance general overview
of this large and multidimensional dataset, we condensed
each metabolite-dose curve into a single value using an
algorithm that identifies the lowest concentration at which
a metabolite concentration deviates from its reference state
in untreated cells. Thereby we can distinguish metabolites
that are generally constant from those that exhibit a drug-
dependent trend. In particular, we were interested in
identifying metabolites that respond already to sub-toxic
drug concentration. Specifically, changes were defined as
early if occurring within the three lowest concentrations
tested, which correspond to doses lower than one tenth of
the toxic concentrations that decrease growth rate (Fig. 2a).
In sharp contrast to the flux data, the high-throughput
metabolome data revealed at least one early change at sub-
toxic dosage in 90% of the cases (i.e. 37 out of 41 drugs,
Fig. 3). At least one late (i.e. at higher drug dosage) change
was observed for 29 compounds, 17 of which also exhib-
ited a growth defect. On average more than five early
changes and two late changes were observed per drug
before growth was affected, but there were striking dif-
ferences between drugs. Specifically, 15 drugs exhibited
less than five metabolite changes at sub-toxic dosages (cfr.
Group A in Fig. 3), 14 drugs showed five to ten changes
(cfr. Group B), and 12 drugs were characterized by more
than ten changes (cfr. Group C). In the latter group, caf-
feine and suramin were two outliers with particularly
widespread changes. While caffeine is known to inhibit
proteins involved in the regulation of a wide variety of
biological process (Reinke et al. 2006), suramin targets the
DNA recombination machinery and thus affects genomic
stability (Porcu and Chiarugi 2005; Schuetz et al. 2007).
Group A with the fewest changes consists mostly of drugs
from the therapeutic groups I, II and III that failed to
impact growth even at the highest dosage. These drugs
either lack a relevant target in yeast, are not transported, or
elicited changes that are not detectable by screening
responses in primary metabolism. For instance, fenofibrate
binds to the peroxisome proliferator activated receptor
alpha (Supplementary Table 1) that does not exist in yeast.
Nimodipine and nifedipine target ion transporters that are
likely to escape our screen because ions were not moni-
tored. The highly diverse-changes group C, in contrast,
consists mostly of drugs that inhibit central, amino acids
and nucleotide metabolism and, in turn, growth. Finally,
drugs in the group B belong to various therapeutic groups
(III, IV, V, VI and VII).
One key goal of such screening methods is drug target
identification. For few drugs such primary target identifi-
cation was in principle possible because the target was
close to a detected metabolite. A good example is the
pyruvate dehydrogenase inhibitor oxythiamine, whose
supplementation caused only four metabolite responses,
two of which were substrate and product of the reaction,
pyruvate and acetyl-CoA. Another example is sulfometu-
ron-methyl that inhibits the valine biosynthesis enzyme
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acetolactate synthase (Supplementary Table 1) and led to
decreased concentration of the pathways product valine.
The coverage of the presently employed metabolomics
method, however, was not ideally suited to identify pri-
mary drug targets outside of primary metabolism.
3.5 Early cytotoxicity prediction from metabolome
profiles
Surprisingly, several metabolite shifts were reproducibly
detected at drug levels well below the highest non-toxic
concentration (cfr. green squares in Fig. 3). These early
changes in metabolites were not necessarily in the imme-
diate vicinity of the known target. For example, sugar
levels often increase upon drug insult (cfr. hexoses, pen-
toses, and disaccharides in Fig. 3), indicating a mobiliza-
tion or a production of storage carbohydrates upon a
general stress (Wiemken 1990). The existence of conserved
early changes in metabolome profiles in response to non-
toxic drug treatment potentially enables to predict toxicity
before it is physiologically manifested in the growth rate.
For this purpose, we resorted to machine learning to
train a classifier. Specifically, we attempted to predict
cytotoxicity from the trajectories of metabolites measured
at three consequent sub-toxic drug concentrations. Tech-
nically, toxicity is defined as a drop in the growth rate,
which results in a kink in the growth rate profile. Impor-
tantly, we set out to use raw data and only removed single
data points that were not reproducible, thus bypassing the
filtering procedure (Fig. 2b) that requires the measurement
of full drug-response profiles. To cope with gaps in the data
set, we trained a 3-nearest neighbor classifier operating
at pair-wise distances, and applied a forward–back-
ward selection procedure to filter uninformative features.
The training procedure identified ornithine, glutamate,
citrulline, a-ketoglutarate, and fructose-bis-phosphate as
the most informative metabolites for toxicity prediction on
all drugs. The classifier performed well on the training
dataset (Fig. 4). In general, the classifier successfully pre-
dicts drug toxicity (i.e. reduced growth rate) from rather
low sub-effective concentrations of most tested drugs.
Sporadically, misclassifications occur in gemfibrozile,
iodoacetate, bumetamide, caffeine, fenpropimorph, and
orlistat. Only in the case of suramin, the classifier consis-
tently fails to correctly interpret the metabolome profiles
because the metabolites vary strongly despite the absence
of a detectable growth defect. It is possible, however, that
toxic effects indeed occur at the next higher, not tested
concentration. We validated the classifier with two cross
validation experiments, and performed permutations tests
to check for overfitting (Supplementary Fig. 6). Based on
these tests we conclude that a balanced error rate of 24% is
a well-justified estimate of the generalization error of the
proposed classification model. Furthermore, the cross val-
idation experiments showed only a marginal higher sensi-
tivity than specificity for cytotoxicity (Supplementary
Table 6).
4 Concluding remarks
Overall, we conclude that independent of the drug class,
the specific mechanism of action, or the absolute drug
concentration, the classifier correctly predicts growth
defects that occur at higher dosage from metabolome tra-
jectories in three quarters of the cases. This also suggests
the existence of metabolome pattern that are characteristic
of a stress response at lower drug concentrations that pre-
cede physiological cytotoxicity. These results demonstrate
that the composition of the metabolic network in terms of
its metabolite concentrations is very sensitive to drug
treatment, while the functional network output in terms of
metabolic fluxes is rather robust, until growth is compro-
mised. This robustness of the fluxome response is consis-
tent with findings using genetic perturbations (Fendt et al.
2010b; Fischer and Sauer 2005). The sensitive metabolome
response, in contrast, renders metabolomics a very prom-
ising methodology for biomarker and toxicity screening.
As demonstrated here with more than thousand samples
analyzed per day on one instrument, metabolomics eclipses
flux and other omics methods by at least one order of
magnitude in terms of throughput and cost. The presented
yeast cytotoxicity data cannot be directly translated to
humans, as illustrated by the apparent absence of growth
and metabolome effects of troglitazone—yet the drug was
removed from the market for high incidents of liver dam-
age. Reasons include the absence of many drug targets in
yeast (Supplementary Table 1) and the fact that many of
Fig. 3 Metabolite profile effect map in response to drug treatment.
The color code indicates at which drug concentration a metabolite
response was detectable (according to the procedure shown in
Fig. 2b), where green and red specify responses that occur at very
low/medium and red at higher drug concentrations (see the bottom
inset for definition). Increasing and decreasing metabolite concentra-
tions are indicated by plus and minus, respectively. Black squares
indicate metabolites that changed with or after growth decreases, gray
squares indicate unaltered metabolites, and white squares highlight
noisy metabolites that were filtered out. The precise drug dosage at
which the physiological growth effect occurs is given in parentheses
behind the drug names. The letter below the drug names indicates the
number of metabolite changes that were induced by the drug; i.e.
A 0–4, B 5–10 and C more than 10 metabolites. Drugs are classified
according to their therapeutic area: group I: anti-hypercholesterolemia
agents; group II: anti-diabetes agents; group III: anti-hypertension
agents; group IV: anti-obesity agents; group V: antifungal; group VI:
anti-cancers agents; group VII: inhibitors of the central carbohydrates
metabolism; group VIII: stimulant
b
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the mammalian drug-metabolizing enzymes are not present
in yeast. The presented approach to rapidly detect or
anticipate cytotoxic side effects, however, is generally
applicable beyond microbes also to higher cells. Obvi-
ously, human cytotoxicity should be investigated in human
cell lines to which the sample processing workflow can be
adapted. More importantly, the prediction power can be
significantly increased by using high-resolution mass
spectrometers to resolve hundreds of metabolites, possibly
in a dynamic fashion.
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